Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship*

Pharmacokinetics of First-Line Tuberculosis Drugs in Tanzanian Patients

(2013) Alma Tostmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State

(2013) Patty Fan-Havard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study

(2013) Anne F. Luetkemeyer et al.   CLINICAL INFECTIOUS DISEASES

Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia

(2013) Julie Bertrand et al.   JOURNAL OF INFECTIOUS DISEASES

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

(2013) Maryline Bonnet et al.   LANCET INFECTIOUS DISEASES

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

(2012) Andrew Scourfield et al.   AIDS

Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians

(2012) Julie Bertrand et al.   Pharmacogenetics and Genomics

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania

(2012) Sabina Mugusi et al.   PLoS One

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

(2011) Tanuja N. Gengiah et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis

(2011) François-Xavier Blanc et al.   NEW ENGLAND JOURNAL OF MEDICINE

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

(2011) Diane V. Havlir et al.   NEW ENGLAND JOURNAL OF MEDICINE

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study

(2011) G Yimer et al.   PHARMACOGENOMICS JOURNAL

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

(2010) Sumonmal Uttayamakul et al.   AIDS Research and Therapy

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Regimens in HIV‐Infected Patients Receiving Rifampicin: The N2R Study

(2009) Weerawat Manosuthi et al.   CLINICAL INFECTIOUS DISEASES

Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis

(2009) Alberto Matteelli et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES